Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Kirk N. Campbell's publication output changed over time?
ScholarIQpublication output · 2008–2026
Output grew0% over the shown period — from 1 works in 2008 to 1 in 2026.
1
1
1
1
3
1
1
1
1
1
2008201020132017201820202022202320242026
What are the most-cited papers on Kirk N. Campbell?
ScholarIQmost cited works
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
Christian Faul, Mary Donnelly, Sandra Merscher, Yoon Hee Chang, Stefan Franz, Jacqueline Delfgaauw, Jer-Ming Chang, Hoon Young Choi, Kirk N. Campbell, Kwanghee Kim, Jochen Reiser, Peter Mündel
Nature Medicine. 2008991 CitationsOPEN ACCESS
Abatacept in B7-1–Positive Proteinuric Kidney Disease
Chih Chuan Yu, Alessia Fornoni, Astrid Weins, Samy Hakroush, Dony Maiguel, Junichiro Sageshima, Linda Chen, Gaetano Ciancio, Mohd Hafeez Faridi, Daniel S. Behr, Kirk N. Campbell, Jer Ming Chang, Hung Chun Chen, Jun Oh, Christian Faul, M. Amin Arnaout, Paolo Fiorina, Vineet Gupta, Anna Greka, George W. Burke, Peter Mündel
New England Journal of Medicine. 2013380 CitationsOPEN ACCESS
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt, Richard Lafayette, Jens Kristensen, Andrew Stone, Daniel Cattran, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Brad H. Rovin, Guillermo Fragale, Alejandra Karl, Patricia Losisolo, Hernán Trimarchi, Ivan Gonzalez Hoyos, Mauro Lampo, Matías Monkowski, Jorge de la Fuente, Magdalena Alvarez, Daniela Stoppa, Carlos Chiurchiu, P. Novoa, Marcelo Orías, Maria Belen Barron, Ana Paula Giotto, M. Arriola, Evelin Cassini, Rafaël Maldonado, Maria Paula Dionisi, Jessica Ryan, Nigel D. Toussaint, Grant Luxton, Chen Au Peh, Vicki Levidiotis, Ross S. Francis, Richard Phoon, Elena Fedosiuk, D.M. Toropilov Toropilov, R. E. Yakubtsevich, Elena Mikhailova, Christophe Bovy, Nathalie Demoulin, Jean‐Michel Hougardy, Bart Maes, Marijn M. Speeckaert, Louis‐Philippe Laurin, Sean Barbour, Mélanie Masse, Michelle Hladunewich, Heather N. Reich, Serge Cournoyer, Karthik Tennankore, Sean Barbour, Jicheng Lv, Zhangsuo Liu, Caili Wang, Shaomei Li, Qun Luo, Zhaohui Ni, Tiekun Yan, Ping Fu, Hong Cheng, Bi‐Cheng Liu, Wanhong Lu, Jianqin Wang, Qinkai Chen, D. Wang, Zuying Xiong, Menghua Chen, Yan Xu, Jiali Wei, Pearl Pai, Lianhua Chen, Jitka Řehořová, Dita Maixnerová, Roman Šafránek, Ivan Rychlík, M Hrubý, Satu Mäkelä, Kati Vääräniemi, Fernanda Ortiz, É. Alamartine, Maïté Daroux, C. Cartery, François Vrtovsnik, Jean‐Emmanuel Serre, Eleni Stamellou, Volker Vielhauer, Christian Hugo, Klemens Budde, Britta Otte, Martin Nitschke, Evangelia Ntounousi, Ioannis Boletis, Αikaterini Papagianni, Dimitrios Goumenos, Kostas Stylianou, Synodi Zermpala
Kidney International. 2022218 CitationsOPEN ACCESS
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants
Ogo Egbuna, Brandon Zimmerman, George Manos, A H Fortier, Madalina Chirieac, Leslie Dakin, David J. Friedman, Kate Bramham, Kirk N. Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J. Falk, Debbie S. Gipson, Michael S. Lipkowitz, Akinlolu Ojo, Mark E. Bunnage, Martin R. Pollak, David Altshuler, Glenn M. Chertow
New England Journal of Medicine. 2023211 Citations
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids
Jonas Sieber, Maja T. Lindenmeyer, Kapil Kampe, Kirk N. Campbell, Clemens D. Cohen, Helmut Hopfer, Peter Mündel, Andreas Werner Jehle
S200780590. 2010201 CitationsOPEN ACCESS
Related on ScholarIQ
University of Pennsylvania
Institution
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
Paper
Abatacept in B7-1–Positive Proteinuric Kidney Disease
Paper
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Paper
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants
Paper
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids
Paper